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Abstract
The newly synthesized proteins are kept in the endoplasmic reticulum (ER)
until their maturation is completed. The accurate protein folding is vital for
homeostasis, but this process is error-prone since it is chemically complicated.
Aberrant folding may result in aggregates having a toxic gain of function or may
lead to a loss of protein function; therefore, protein misfolding can lead to several
pathologies. The ER protein quality control mechanism monitors the fidelity of
protein folding. Those proteins that fail to fold or assemble properly are subjected to
degradation via a process known as ER-associated degradation (ERAD). Besides
clearing proteins having folding problems, ERAD is also known to regulate the
levels of some physiological proteins including 3-hydroxy-3-methylglutaryl-
coenzymeA reductase (HMGR) catalyzing the rate-limiting step of cholesterol bio-
synthesis. ERAD is a complex, multistep process starting with the recognition and
targeting of substrates, followed by ubiquitination, retrotranslocation and
proteasomal degradation. A large number of ERAD factors functioning in different
molecular machineries increases the complexity of mammalian ERAD. ERAD is
fundamental for human health and there is increasing evidence linking ERAD with
various diseases. Here, the different modules/machineries of the ERAD process
together with its tight regulation will be discussed.
Keywords: endoplasmic reticulum-associated degradation (ERAD), protein
misfolding, ubiquitin-mediated degradation, proteasomal degradation
1. Introduction
The endoplasmic reticulum (ER) is an extensive network of flattened,
membrane-enclosed tubes or sacs that extends throughout the cytosol [1]. ER has
important roles in many biochemical processes required for cell survival and normal
cellular functions. ER regulates these cellular processes through proteins that are
localized in its complex network structures [1–3]. In addition to protein synthesis,
significant cellular activities such as protein transport and folding, lipid and steroid
synthesis, carbohydrate metabolism, calcium storage and protein quality control
processes occur in the ER [1–4].
Approximately one-third of all newly synthesized proteins are targeted to the ER
and traffic to other organelles of secretory pathway, plasma membrane or the
extracellular space [5]. Protein translocation to the ER occurs through Sec61 com-
plex [6, 7]. As synchronized with translocation, protein is exposed to the ER’s
oxidizing and calcium-rich environment, which is suitable for protein folding and
1
co- and post-translational modifications such as glycosylation, disulfide bond for-
mation and glycosylphosphatidylinositol (GPI) anchoring [8]. During this folding
process, many proteins such as lectin-type molecular chaperones (e.g., calnexin
(CNX) or calreticulin (CLR)), HSP70-like chaperone BiP) and enzymes like protein
disulfide isomerases (PDI) work in association with each other [4, 9, 10]. Confor-
mational maturation and folding of the proteins in the ER are instantly controlled
through the added N-glycan groups to decide whether the proteins are directed to
distant compartments via the secretory pathway or included in the refolding cycle
[11, 12].
The folding process is not completely accurate. In mammals, 30% of all newly
synthesized proteins are estimated to be incorrectly folded [13]. However, genetic
mutations, errors in transcription and translation, toxic compounds and cellular
stresses such as defects in cellular redox regulation due to hypoxia, oxidants and
reducing agents that interact with disulfide bonds in the ER lumen, glucose starva-
tion and abnormalities in calcium regulation lead to a significant increase in the
ratio of incorrectly folded proteins [4, 11, 14]. Adequate removal of these unwanted
proteins is crucial for protecting cells from proteotoxicity caused by the formation
of protein aggregates through the re-opening of hydrophobic residues as well as by
unfolded or misfolded proteins that may compete with their properly folded coun-
terparts for substrate binding or for complex formation with partners. Even though
the primary damage of these unwanted proteins is restricted to the cell they reside,
the damage gets wider if it is a secretory protein [11]. Therefore, there is a robust
control via “Protein Quality Control Mechanisms” for the removal of defective
proteins in living cells, and thus, only properly folded proteins are allowed to exit
from ER lumen to the secretory pathway [11, 15–18]. When the folding process
fails, the terminal mannose residues from the core glycan chain are gradually
removed, allowing the proteins to be recognized by mannose-specific lectins and
defective proteins are transferred to the 26S proteasome for degradation through
the protein quality control mechanism called “ER-associated degradation (ERAD)”
[19–21].
In addition to misfolding proteins, ERAD also targets some proteins that might
fold into their native structures under the right conditions and also orphan subunits
of oligomeric complexes. The chloride channel protein CFTR (cystic fibrosis trans-
membrane conductance regulator) is the best example, where it is targeted to ERAD
as a consequence of its complex and inefficient folding pathway. The low folding
efficiency is further decreased upon mutation as seen in CFTR∆F508. CFTR∆F508
is the most common mutation found in cystic fibrosis patients, can fold and func-
tion in plasma membrane; thus, degradation of CFTR via ERAD is obtrusive. ERAD
also functions in supporting the correct stoichiometry of multimeric protein com-
plexes by degrading components that are produced in excess of the limiting mono-
mer [22]. For example, the unassembled subunits of T cell receptor-like TCRα and
CD3δ are also well-known ERAD substrates [23]. These proteins contain charged
residues in the intramembrane sections promoting the assembly of complexes.
However, when oligomerization is not proper, these residues might initiate degra-
dation via recruiting specific ERAD factors [23].
ERAD also functions in cell homeostasis by regulating the endogenous levels of
many enzymes and signal molecules especially those localized to the ER membrane
or plasma membrane under physiological conditions [24]. For instance, ERAD plays
a homeostatic role in the regulation of HMG-CoA reductase (HMGR), which is the
key enzyme of cholesterol metabolism; apolipoprotein B, an essential secreted pro-
tein member of triacylglycerol-rich lipoproteins responsible for the export of lipids,
triglycerides and cholesterol; hepatic cytochrome P450 enzyme 3A4 metabolizing
endo- and xenobiotics; IP3 receptor, an ER-localized protein allowing Ca2+ release
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by binding seconder messenger inositol 1,4,5-triphosphate (IP3); type II
iodothyronine deiodinase, an ER-localized enzyme converting thyroxin (T4) to the
biologically active hormone triiodothyronine (T3) and GABA neurotransmitter
receptor responsible for the reduction of neuronal excitability and the tumor
metastasis suppressor KAI1 levels [22, 25–28].
Some viruses hijack the ERAD system through encoding effectors by serving as
adaptors that redirect correctly folded molecules towards degradation. US2 and
US11, the human cytomegalovirus gene products, induce degradation of major
histocompatibility complex (MHC) class I heavy chain, which enables virus-
infected cell to avoid detection by the immune system [29]. Similarly, Vpu is a
glycoprotein encoded in the human immunodeficiency virus (HIV-1) genome and
binds and targets newly synthesized CD4 for degradation [30], allowing them to
evade immunosurveillance. Moreover, toxins like diphtheria, cholera and ricin
enter the cell by endocytosis and move to the ER. They use the ERAD system to
escape from the ER lumen and gain access to their enzymatic substrates in the
cytoplasm [31].
ERAD is a highly complicated and regulated mechanism in which the diversity
and combination of components change according to the protein to be destroyed
[19–21, 32]. Maturation-defective proteins are removed from the ER lumen or lipid
bilayer by retrotranslocation through the ERAD pathway and degraded by
proteasome. The ubiquitin system is an integral part of the ERAD and is composed
of factors necessary for the recruitment, processing and binding of ubiquitin chains
to substrates [24]. In other words, ERAD is composed of steps that include substrate
selection, modification with ubiquitin chain, retrotranslocation and 26S
proteasomal degradation. Several key molecules such as E1, E2, and E3 enzymes
responsible for ubiquitin transfer, channel components responsible for retrotran-
slocation, chaperones and cofactor proteins function in a synchronized manner
during ERAD pathway [12, 19–21].
This critical role of ERAD in the regulation of cell homeostasis is an evident that
ERAD disorders will have important effects on cell survival. Furthermore, it has
been shown that aberrations in ERAD function play a role in the pathology of nearly
70 diseases such as cystic fibrosis, α1-antitrypsin (AAT) insufficiency, diabetes,
neurodegenerative diseases (Parkinson, Alzheimer's and Huntington's diseases),
viral infection and albinism [4, 33].
In this section, the knowledge related to the basic mechanism and regulation
patterns of the ERAD will be summarized and presented.
2. Molecular mechanisms of ERAD
2.1 Protein folding process and recognition of misfolded proteins
About 30% of the total proteins and all transmembrane proteins of the cell are
synthesized in the ER, which acts as a portal for entry into the secretory pathway
via the Sec61 channel [7–8]. As being translocated, the N terminal hydrophobic
signal sequence of newly synthesized protein is cleaved by a peptidase complex
[34]. Co- and post-translational modifications such as disulfide bond formation,
initial steps of N-glycosylation, and glycophosphatidylinositol (GPI) anchorage take
place in the ER.
The oxidizing environment of ER assists the formation of disulfide bonds, which
stabilizes tertiary protein structure and facilitates protein assembly. During the
folding process, disulfide bonds are formed through the oxidation of pairs of free
thiols on cysteine residues by protein disulfide isomerases (PDIs). PDIs act as
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cycles, and after initial oxidation, disulfide bonds are sometimes isomerized by PDI
and ERp57, which is a thiol oxidoreductase, in order to stabilize the correct folding
of protein [35]. Conversely, the reduction of disulfide bonds of misfolded proteins
is necessary for retrotranslocation step of ERAD. Indeed, PDI enables the
retrotranslocation of the simian virüs-40 (SV-40) and cholera toxin [36, 37]. ERdj5,
an ER oxidoreductase, reduces disulfide bonds and interacts with EDEM (ER-
degradation enhancing mannosidase-like protein) and also accelerates the step of
retrotranslocation of SV-40 [37]. ERDJ5 also regulates the degradation of disease-
causing α1-antitrypsin variant (null Hong Kong) [38].
Folding is aided by molecular chaperones shepherding against misfolding and
unfolding. Chaperone-like glycans bind to N-glycans playing a crucial role in pro-
tein folding and degradation. It is apparent that N-glycosylation, quality control of
protein folding and ERAD are functionally linked. After entering to the ER, a large
majority of the newly synthesized polypeptide chain are being N-linked
glycosylated. The oligosaccharyltransferase enzyme recognizes the Asn-X-Ser/Thr
consensus sequence in the most of the nascent protein molecule and covalently
integrates a high mannose containing core glycan groups (Glc3Man9GlcNAc2) from
dolichol localized on the ER membrane to the protein [39]. Due to the very short
half-life of triglycosylated form of protein-bound oligosaccharide, glycan
processing starts immediately after the transfer of precursor glycan groups through
glucosidase enzymes. Following cleavage of two of three glucose residues, the
nascent protein could interact with quality control lectins like CNX and CLR. This
interaction is preserved until cleavage of remaining glucose residue. After releasing
the glycoprotein from CNX/CLR cycle, final glucose is also trimmed creating
unglycosylated substrate. This compromises the interaction of substrate with the
lectin chaperones. At this stage, if protein is properly folded, it could exit the ER for
their final destination. However, if glycoprotein is still unfolded, it is retained in the
ER and reglucosylated by UDP-glucose:glycoprotein glucosyltransferase and
rebound with CNX and CLR giving protein more time for proper folding [40, 41]. It
is not yet understood the mechanisms involved in the termination of
reglycosylation/deglycosylation cycles. However, it is clear that, if the polypeptide
chain cannot reach its mature form after repeated folding attempts, terminal man-
nose residues from the core glycan chain are gradually removed by ER α1,2-
mannosidase I (ERMan1). ERMan1 produces Man8GlcNAc2 isomer by removing a
mannose residue from the middle branch of N-glycans. By this trimming,
glycoprotein becomes poorer substrates for reglycosylation and exit from the
CNX cycle [11].
The hydrophobic patches of properly folded proteins are usually buried within
the interior of soluble proteins. However, those patches could be exposed in
misfolded proteins. If a protein has exposed hydrophobic surfaces, BiP binds to it in
order to hide these aggregation-prone surfaces for proper folding attempts by
preventing aggregation. However, if folding does not succeed or delayed, extended
chaperone-misfolding protein interaction serve for a sophisticated process where
protein is transferred to other chaperones and/or to the ERAD process [27, 42].
It is well accepted that the first step of ERAD is selection of misfolded proteins
by chaperones. As early as 1999, it was found that yeast ERAD substrates strikingly
differed in their requirement for the ER-luminal Hsp70, BiP [43]. The degradation
of soluble substrates such as pαF and a mutant form of the vacuolar protease
carboxypeptidase Y* (CPY*) were dependent on BiP, while degradation of trans-
membrane proteins Pdr5*p, Ste6-166p, Sec61-2p and Hmg2p occurred in a BiP-
independent manner. In 2004, it has been shown that substrates with cytosolic
domain such as Ste6-166p were degraded BiP-independently, while proteins with
luminal defects required BiP, suggesting that depending on the topology of
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misfolded lesion (ER lumen, ER membrane and cytoplasm) cytosolic or luminal
chaperones function in the recognition and targeting for the degradation [44].
It is possible to study substrate recognition during ERAD using model misfolded
proteins. It is clear that de-mannosylation is required for degradation of misfolded
glycoproteins since inhibition of this mannose trimming stabilizes misfolded glyco-
proteins in the ER [45]. Overexpression of ERMan1 accelerates the degradation of
N-glycosylated proteins [39, 46]. The resulting Man8-GlcNAc2 containing glyco-
protein after this trimming becomes a substrate for EDEM1 (ER-degradation
enhancing mannosidase-like protein 1, Htm1p in yeast)—a mannosidase-related
lectin in the ER. It was further proposed that misfolded glycoproteins interact with
ERManI and EDEM1 for their ERAD, and lectin-carbohydrate interaction found
to be crucial for EDEM substrate recognition [47]. Although ERMan1 was suggested
to be a biological timer initiating the ERAD of misfolded proteins [48], recent
studies revealed that mannosidases are not solely responsible for intensive
demannosylation during ERAD, especially under non-basal conditions. Under ER
stress (unfolded protein response active) conditions, the transcriptional elevation of
EDEM1 enhances the ERAD efficiency by suppressing proteolytic downregulation
of ERMan1 [49]. It appeared that EDEMs also play an important role in
demannosylation of substrates [50]. EDEM1 also prevents reglycosylation and pro-
motes retrotranslocation and degradation of some ERAD substrates [51]. On the
other hand, while mannosidase homology domain (MHD) of Htm1p is necessary for
substrate binding, mammalian EDEM1 binds misfolded proteins independent of
MHD domain, and therefore, EDEM1 substrate binding may not require mannose
trimming or even glycosylation [52]. Thus, in addition to N-linked oligosaccharide
moieties of glycoproteins, EDEM1 can recognize the folding lesions of misfolded
proteins. In summary, EDEMs are directly or indirectly involved in
demannosylation of glycoproteins and/or serve as receptors that bind and target
mannose-trimmed proteins for ERAD (Figure 1).
Truncation of terminal mannose from branch C exposes α terminal α1,6-bonded
mannose residues functioning as a recognition signal for ERAD lectins such as OS9
(Yos9 in yeast) and XTP3-B (Figure 2). Through their mannose-6-phosphate
receptor homology (MRH) domain, both proteins primarily recognize α1,6-linked
mannose j. Additionally, OS-9 also recognizes α1,6-linked mannose e and c [53].
Several reports suggest that factors (EDEMs, OS9 and XTP3-B) required for
substrate recognition and targeting reside within supramolecular complexes and/or
interact with important ERAD regulators [54]. For example, EDEM1 interacts with
CNX, receives substrates from CNX cycle and facilitates ERAD substrate
Figure 1.
Protein quality control and targeting misfolding proteins to the ERAD.
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degradation such as NHK-α1-antitrypsin mutant [55–57]. EDEM1 also associates
with the components of ER retrotranslocation machinery. It is suggested that
EDEM1 binds misfolded proteins and uses its MHD domain to target aberrant pro-
teins to the ER-resident glycoprotein SEL1L protein of the Hrd1-SEL1L ubiquitin
ligase complex [58]. SEL1L scaffolds several luminal substrate recognition factors
and links them to Hrd1. OS9 and XTP3-B also associate with Hrd1-SEL1L complex,
which also includes BiP and GRP94 [59, 60]. Furthermore, XTP3-B is proposed to
link BiP with Hrd1 complex [60]. According to a hypothesis, these three chaperones
(EDEM1, OS9 and XTP3-B) function as oligomers, where one monomer interacts
with substrate and another with Hrd1-SEL1L complex [61]. Additionally, EDEM1
also interacts with Derlins, a transmembrane protein, which is a candidate for
translocon [62]; furthermore, Derlin2 is shown to enhance the interaction of
EDEM1 with a cytosolic AAA-ATPase p97, which couples ATP hydrolysis to the
retrotranslocation of misfolded proteins [50].
It is clear that substrate recognition step of ERAD is a complicated mechanism,
in which several different enzymes and chaperones having distinct but concerted
roles in the ERAD are involved. Moreover, depending on substrates, the number
and features of involved proteins vary. For example, concerted roles of EDEM,
ERdj5 and BiP in the degradation of misfolded proteins have been suggested [63].
After exiting CNX-CLR cycle, EDEM1 further trims the Man8-GlcNAc2 glycan
structure and ERdj5 reduces disulfate bonds. Concomitantly, ERdj5 activates BiP’s
ATPase activity. ADP-bound BiP binds to the misfolded protein and holds it in a
retrotranslocation component form until it transfers to the retrotranslocation com-
plex [63].
ERAD is also involved in the quality control of non-glycosylated proteins, which
is independent of lectin-like proteins. Immunoglobulin light chain (Ig-K-LC), a
non-glycosylated ERAD substrate, is degraded in a BiP-dependent manner. Okuda-
Shimizu and Hendershot have characterized an ERAD pathway for this non-
glycosylated BiP substrate [64] and different protein interaction dynamics seen to
play a role in this process. Ig-K-LC has two intramolecular disulfide bonds, and its
fully oxidized form does not have ability to pass from the ER to the cytoplasm. BiP
interacts with only partially oxidized form of the Ig, preventing the full oxidation of
Ig-K-LC and thereby facilitating its release from the ER [64]. Furthermore, a trans-
membrane UBL domain-containing protein, homoCys-responsive ER-resident
protein (HERP), has been implicated as a receptor for non-glycosylated BiP
Figure 2.
Schematic representation of ERAD using the Hrd1 complex as model.
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substrates [64]. HERP interacts with Derlin1, and the partially oxidized Ig-K-LC is
transferred from BiP to the HERP-Derlin1-Hrd1 complex and subsequently directed
to proteasomal degradation [65]. Besides BiP, ERdj5 as disulfide reductase is also
indicated to be important for ERAD of non-glycosylated proteins [63]. The non-
glycosylated substrates captured by BiP are transferred to ERdj5 for the cleavage of
disulfide bonds. Then, these substrates are transferred to SEL1L by the help of BiP
for retrotranslocation [63]. Besides BiP, both OS9 and XTP3-B have been implicated
in the ERAD of non-glycosylated proteins [12].
2.2 Ubiquitination
Ubiquitin is a 76 amino acid polypeptide encoded on multiple genes. It is ubiq-
uitously expressed in all eukaryotic cells and highly conserved from yeast to human.
Ubiquitin can be covalently conjugated to other proteins as monomers or as chains
through a complex, highly regulated process called ubiquitination. Although there
are reports for evidence of Ser- and Thr-linked ubiquitination, ubiquitin chain is
generally attached on the Lys residue on misfolded protein. Lys-6, -11, -27, -29, 33,
-48 and -63 are the residues used for ubiquitin linkage. Both the type of
ubiquitination (mono/poly) and the linkages of ubiquitin chains affect the fate,
localization, stability and activity of target proteins [9].
Ubiquitination has a regulatory role in almost all cellular processes by altering
the fate and function of the proteins. The most well-established role of
ubiquitination is targeting proteins for degradation by the 26S proteasome, and the
most efficient way of targeting proteins to the proteasome is by tagging them with
chains of ubiquitin [66]. This targeting requires modification of proteins with
chains of four or more ubiquitins attached through lysine 48 (K48) and the specific
recognition of these chains by the 19S cap of the 26S proteasome [67]. Mainly Lys-
48 but rarely Lys-11-based polyubiquitin chains are reported to bind onto ERAD
substrates [68].
Ubiquitination regulates several critical cellular functions, often by mediating
the selective degradation of important regulatory proteins. Antigen presentation,
inflammatory response induction and cell cycle progression are few examples. As
expected, malfunctioning of ubiquitin-dependent proteolysis has implications for
cancer and several inherited diseases, such as Angelman syndrome, Parkinson’s
disease and Alzheimer’s disease [69].
The role of ubiquitination, however, is not limited to proteasomal targeting. The
type of residue that the chain is built is critical for the fate of the ubiquitinated
protein. Monoubiquitination has effects in protein trafficking, including endocyto-
sis and lysosomal targeting. Polyubiquitin chains conjugated through K48 or other
lysines (often K63) also have effect on proteasome-independent mechanisms,
such as DNA repair, regulation of transcription factor activity and protein kinase
activation [70].
Ubiquitination is a multi-enzyme process. Three enzymes are involved: E1-
ubiquitin activating enzyme, E2-ubiquitin conjugating enzyme and E3-ubiquitin
ligase. During ubiquitination, E1 forms a thiol-ester bond between its active
cysteine and C-terminal glycine of ubiquitin in an adenosine triphosphate (ATP)-
dependent manner. Ubiquitin on E1 is now activated and transferred to the active
cysteine of E2 by a trans-thiolation reaction. E3 binds both to E2 and substrate and
facilitates the formation of an isopeptide linkage between C-terminal glycine of
ubiquitin and an internal lysine residue on substrate. Ubiquitin modification is
dynamic and could be removed by deubiquitination enzymes (DUBs).
Today only 2 E1 enzymes and 35 E2 enzymes have been identified in mammals,
but there are approximately 100 E3 in yeast and at least 600 in humans [71, 72]. E3s
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catalyzing the transfer of active ubiquitin moieties on the substrate are responsible
for substrate specificity. There are two large families of E3s: (1) HECT [homologous
to E6-associated protein (E6AP) C-terminus] domain E3s and (2) RING [really
interesting new gene] domain E3s. HECT domain E3s share a 350-residue region
harboring a strictly conserved cysteine residue that forms an essential thiol-ester
intermediate during catalysis. That is why ubiquitin is transferred to the active-site
cysteine of the HECT domain followed by transfer to substrate or to a substrate-
bound multi-ubiquitin chain. The RING finger defines the largest family of E3s.
RING fingers range from 40 to 100 amino acids and are defined by eight conserved
cysteine and histidine residues that coordinate two zinc ions stabilizing a charac-
teristic cross-braced conformation. For RING E3s, current evidence indicates that
ubiquitin is transferred directly from E2 to substrate [69, 70].
Ubiquitination step marks ERAD substrates for proteasomal degradation. In
yeast, Doa10p and Hrd1p ligases are mainly responsible for ubiquitination of ERAD
substrates, but additional E3s shown to contribute to the ERAD under special
circumstances [9]. Depending on the topology of misfolded lesion, factors required
for ERAD vary. In yeast, three ERAD pathways have been proposed. ERAD-C,
ERAD-L and ERAD-M target proteins with lesions in the cytoplasmic, luminal and
membrane domains, respectively [44, 73, 74]. ERAD-L substrates use the Hrd1p
ubiquitin ligase complex containing Hrd1p, Hrd3p, Usa1p, Der1p, and Yos9p,
whereas ERAD-M substrates use Hrd1p and Hrd3p, only in some cases Usa1p [68].
Hrd3p is specifically important for structural integrity of Hrd1p complex. Hrd3p
stabilizes Hrd1p, and when it is absent, Hrd1p is auto-ubiquitinated and rapidly
degraded. Hrd3p and its mammalian homolog SEL1L also function as an adaptor
bridging substrate recognition, ubiquitination and retrotranslocation in Hrd1-
mediated ERAD. On the other hand, ERAD-C substrates interact with the Doa10p
ubiquitin ligase complex. These three pathways have been identified only in yeast
and mammalian has more complicated machinery. Even in yeast, some
membrane proteins require both Doa10p and Hrd1p E3s; thus, these pathways
could overlap [42].
Although Hrd1p and Doa10p are conserved evolutionary (mammalian homo-
logs: Hrd1 and TEB4, respectively), the number of ERAD E3s in mammals is highly
expanded. Besides Hrd1 and TEB4, gp78, RNF5/RMA1, RNF170, RNF185, Trc8,
RNF103, RFP2, Fbx2, Fbx6, Parkin, CHIP and UBE4a are other characterized ERAD
E3s [9, 27]. Hrd1 and gp78, both homologues to yeast Hrd1p, are the most studied
ERAD E3 indicated for degradation of several substrates, some of which are associ-
ated with the quality of disease-related proteins. HMG-CoA reductase, apolipopro-
tein B, cytochrome P450 CYP3A4, CFTRΔF508, z-variant antitrypsin, CD3δ and
KAI1 are shown to be degraded via gp78-mediated ERAD, whereas studies have
been suggested that Hrd1 is important for the ERAD of GABAb receptor, Nrf2,
Pael-receptor mutant tyrosinase, z-variant antitrypsin and gp78 [22, 75–78]. Only a
couple of substrates are known for other E3 ligases. It is also interesting that
multiple E3s often function in the degradation on same substrate either in parallel or
in tandem.
As Hrd1p in yeast, Hrd1 in mammals functions in a multi-protein complex.
While it is complex with EDEM1, Derlins, OS9, XTP-3B and SEL1-L have been
linked with degradation of glycosylated substrates (Figure 2), and another Hrd1
complex utilizing BiP, HERP and Derlin1 functions in the degradation of non-
glycosylated substrates. Other ERAD factors have also been shown to interact with
Hrd1 including UBXD2 and UBXD8 that interact with p97/VCP and recently iden-
tified chaperones such as ubiquilin and BAG6. Similarly, gp78, the second major
mammalian ERAD E3 enzyme, functions in multiprotein complex in conjunction
with E2 enzyme UBE2G2. Besides its diversity on substrate specificity, gp78 also has
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variety of different partners allowing its communication with proteins on both sites
of ER membrane. gp78 uses a VIM (VCP-interacting motif) segment to bind p97/
VCP [77] and CUE domain recruiting a multiprotein complex composed of Bag6
and its cofactors [79].
After initial E3-mediated ubiquitin attachment, ubiquitin chain extension
(“polyubiquitination”) occurs by the covalent modification of additional ubiquitin
monomers onto a Lys residue in a previously linked ubiquitin. This forms an
extended isopeptide-linked polyubiquitin chain. In some selected cases, the coop-
erative extension of a polyubiquitin chain is by the E4s, ubiquitin chain extension
enzymes, that facilitate ERAD [80–82].
2.3 Retrotranslocation and shuttling substrates to the proteasome
The ERAD substrates must be retrotranslocated to the cytosol for proteasomal
degradation and the cytoplasmic AAA+ ATPase p97 (VCP or Cdc48p in yeast) is the
main retrotranslocation protein providing the mechanical force required for
removal of proteins from the ER. It is an essential protein having many roles in
diverse biological processes, such as endoplasmic reticulum-associated degradation
(ERAD), homotypic membrane fusion, transcriptional control, cell cycle regulation,
autophagy, endosomal sorting and regulating protein degradation at the outer
mitochondrial membrane [83–85].
p97/VCP has a multidomain structure including N domain, D1 weak ATPase, D2
major ATPase and C domain [86–88]. p97/VCP functions as a homohexamer and D1
domain is responsible for oligomerization independent of nucleotide binding. The
change in the conformation of hexameric ring by ATP hydrolysis is persistent with
its function in retrotranslocation [88, 89].
The diversity in cellular functions of p97/VCP is dictated by the variety of its
partner proteins that interact with its N domain. p97/VCP associates with several E3s
like Hrd1 and gp78, DUBs like ataxin3 and YOD1 and ERAD accessory factors such as
UbxD2 and VIMP. Moreover, many p97/VCP interacting proteins (Ufd1-Npl4 dimer,
gp78 etc.) bind directly to ubiquitin. p97/VCP functions as a segregase using the
energy from ATP hydrolysis to segregate ubiquitinated proteins from large immobile
complexes of ER to the cytosol. This cytosolic protein is recruited to the ER mem-
brane through its interaction with membrane-embedded ERAD components. There
are at least seven different ERAD members that could interact with p97/VCP via
certain motifs such as VIM motif (gp78 and SVIP), UBX domains (UBXD2 and
UBXD8), SHP boxes (Derlin1 and Derlin2) and uncharacterized cytosolic regions of
Hrd1 and VIMP that found to have p97/VCP-binding motif [12, 42, 90].
Retrotranslocation is tightly coupled with both ubiquitination and proteasomal
degradation. In most cases, inhibiting ubiquitination prevents both degradation and
retrotranslocation. The interaction of p97/VCP/CDC48p with its cofactor Ufd1-
Npl4 dimer enhances its affinity to ubiquitin (Figure 2). However, it has been also
suggested that Hrd1-mediated ERAD requires well-established retrotranslocation
machinery, the p97/VCP–Ufd1–Npl4 complex, whereas the gp78 pathway needs
only p97/VCP and Npl4 [75].
Many deubiquitinating enzymes (DUBs) in mammalian cells, including Ataxin3,
USP13, USP25 and YOD1, are also implicated in the ERAD through physical inter-
action with ERAD core machinery [72, 91, 92]. Several studies revealed that p97/
VCP interacts with DUBs. However, the function of DUBs in the ERAD is still not
fully characterized. Otu1p (yeast homolog of YOD1) binds to CDC48p and trims the
polyubiquitin chain, resulting oligoubiquitin chains with up to 10 ubiquitin mole-
cules. It has been further suggested that releasing substrates from CDC48p requires
DUBs [93]. Consistently, catalytically inactive YOD1 inhibits retrotranslocation of
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ERAD substrates [91]. In conclusion, many p97-associated DUBs serve as positive
regulators of ERAD.
Several putative retrotranslocation channels have been proposed such as the
Sec61 complex, members of Derlin family and polytopic E3s such as Hrd1 and gp78.
Sec61 is one of the proposed channel protein mutants, which prevented degradation
of some ERAD substrates in yeast [94, 95]. Cholera toxin also translocates from ER
by utilizing Sec61 [96]. On the other hand, retrotranslocation of some other ERAD
substrates has been suggested to depend on Derlins [97, 98], a family of polytopic
transmembrane ER proteins linked to some ERAD substrates. Moreover, Derlin1
recruits p97/VCP [99], a key protein of retrotranslocation, which provides energy
for the process. Derlin1 also interacts with some E3s like Hrd1, gp78 and RNF5
forming large complexes on the ER membrane [9]. Recently, Hrd1 ubiquitin ligase
has been suggested to be the top candidate for retrotranslocation channel [9]. Auto-
ubiquitination of Hrd1p in its RING finger domain triggers conformational change
allowing the misfolded luminal domain of a substrate to move across the mem-
brane. Thus, it was suggested that Hrd1 forms an ubiquitin-gated protein-
conducting channel [33]. It has also been suggested that proteins might exit the ER
via the formation of lipid droplets or lipid droplets serve as an intermediate step for
substrates en route to the proteasome [100]. However, studies in yeast suggested
that lipid droplet formation is dispensable for ERAD-L and ERAD-M [101].
Once retrotranslocated from ER to the cytosol, ERAD substrates should be
rapidly targeted to the proteasome for degradation in order to avoid accumulation
of aggregates in the cytosol. Consistently, proteasomal inhibition also stabilizes
ERAD substrates in the ER lumen. For the coupling of retrotranslocation with
degradation, ubiquitinated substrates must be recognized by cytosolic proteins
functioning as ubiquitin receptors. Ubiquitin-binding domain containing proteins
has ability to shuttle ubiquitinated proteins from retrotranslocation complex at the
ER membrane to the proteasome since these proteins interact both with proteasome
and p97/VCP. Indeed, it has been suggested that p97/VCP bridges the ER to the
proteasome by forming a complex with mHR23B (homolog of yeast Rad23p)-
PNGase [102] (Figure 2). In yeast, the substrates are probably transferred from
CDC48p to the proteasome indirectly via ubiquitin- and proteasome-binding
domains containing shuttling factors Rad23p and Dsk2p [103, 104]. Recently, Bag6/
Bat3/Scythe has been characterized as a novel chaperone system with regulatory
functions in protein degradation [79]. The chaperone holdase activity of this system
keeps some retrotranslocated substrates in a soluble state for proteasome degrada-
tion. Bag6, also a partner protein of gp78 E3 enzyme, interacts with proteasome,
and proteins like ubiquilin that known as proteasome adaptor proteins suggesting
Bag6 might act between p97/VCP and proteasome to hand substrates off from
retrotranslocation machinery to the proteasome.
3. Regulation of ERAD
Regulation of ERAD in normal and pathological conditions is also of great
importance since hyper-ERAD may cause in loss-of-function phenotypes upon
unnecessary degradation of folding intermediates as seen in CFTR and hypo-ERAD
may result in gain-of-function phenotypes upon accumulation and/or aggregation
of misfolded and unassembled proteins. Several studies suggested different regula-
tion paths for ERAD activity via ubiquitin ligases and their dynamic ERAD com-
plexes, UPR and endogenous ERAD inhibitors.
It is thought that ERAD functions at relatively low levels under basal conditions,
but under proteotoxic stress its activity is enhanced. Accumulation of the unfolding
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or misfolding proteins in the ER lumen triggers “ER stress” by decreasing free
chaperone levels [105]. In response to this cellular stress, the pathway known as the
“Unfolded Protein Response (UPR)” is activated and results in specific cellular
functions classified as adaptation, alarm and apoptosis [4]. Three transmembrane
proteins with luminal domains that sense the changes in the ER environment func-
tion as UPR sensor proteins are inositol requiring enzyme-1 (IRE1), activating
transcription factor 6 (ATF6) and protein kinase RNA-like endoplasmic reticulum
kinase (PERK). PERK is a serine/threonine kinase, and IRE1 possesses both kinase
and endoribonuclease domains [27, 50]. These sensors initiate signal transduction
by sensing the presence of unfolded proteins in the ER lumen and thus control the
UPR pathway [15, 18, 106]. All these transmembrane proteins interact with BIP
under basal conditions. However, when unfolded proteins are present, BIP dissoci-
ates from the UPR sensor proteins. After dissociation of BIP, PERK and IRE1
dimerize and become activated by auto-phosphorylation, whereas ATF6 become
translocated to the Golgi and proteolytically cleaved [27, 50]. Activated PERK
phosphorylates translation factor eIF2α attenuating protein synthesis to limit pro-
tein load. IRE1 activates XBP-1 that enhances transcription of ERAD factors
[27, 50]. On the other pathway, ATF6 upregulates many genes that encode ER-
resident chaperones and folding assistants like BIP, CNX, CLR and PDI. To sum-
marize, with the induction of UPR in the cell, the overall translation is inhibited for
several hours primarily to slow down the entry of newly synthesized proteins to the
ER, the amount of chaperones and ER protein folding capacity is increased for
proper folding of accumulated unfolded proteins, and thus, the normal ER function
and homeostasis are protected [4, 107]. UPR also enhances ERAD capacity by
upregulating some of the ERAD genes to ensure that defective proteins are
degraded when the folding attempts fail [21–23]. EDEM proteins, Hrd1, SVIP, OS9
and gp78, are only some of the targets of the ER stress-induced Ire1/Xbp1 pathway
[62, 108–111]. If the cellular stress is consistently increasing, UPR induces cell death
mechanisms such as apoptosis or autophagy [4, 14, 112].
It has been suggested that large or prolonged variations such as change in Ca2+ or
redox homeostasis, exposure to pathogens and large-scale accumulation of
misfolded proteins may induce UPR to adapt ERAD activity. However, smaller or
more transient fluctuations on ER load may be overcome rapidly by post-
translational pathways that control stability, localization and assembly of ERAD
components [23]. For example, reversible ADP ribosylation adapts BIP response for
short-term fluctuations [113]. Reversible palmitoylation changes the sub-organelle
distribution of CNX [114, 115]. Moreover, many ERAD factors/enhancers, includ-
ing EDEM1, ER Man1, HERP, OS9, SEL1L and gp78, have fast turnover. This is
important since when protein misfolding crisis is over, ERAD activity should rap-
idly turn back to the basal levels. Many ERAD factors then rapidly degraded via a
process called ERAD tuning [23]. ERAD tuning does not require signal transduction
from the ER to the nucleus [23]. Hrd1 was suggested to be a central regulator of
ERAD tuning. It has been shown that Hrd1 ubiquitinates gp78 E3 enzyme and
enhances its degradation, which in turn causes inhibition of gp78-mediated ERAD.
Very recently, Hrd1 was also found to regulate the stability of OS9 [116]. Hrd1 also
undergoes auto-ubiquitination to induce its own proteasomal degradation [117].
Another homeostatic control mechanism, in which ERAD activity itself is regulated
post-translationally and independent of UPR, is degradation of EDEM1, OS9
and SEL1L by the E2 enzyme UBC6e, a component of Hrd1 supramolecular
complex [118].
Another type of ERAD regulation occurs via substrate-specific adaptor, as
reported for HMGR. The adaptor proteins, Insig1 or Insig2, bind to HMGR only in
the presence of 24,25-dihydrolanosterol, an intermediate molecule in sterol
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biosynthesis. Under low sterol levels, HMGR is stable; however, when sterol levels
are high, Insig-HMGR interaction become favored, leading delivery of HMGR to E3
complex following by its proteasomal degradation [119]. Likewise, ERAD-mediated
degradations of apolipoprotein and IP3R are initiated when lipid levels are low and
calcium levels are high, respectively [23].
DUBs are also proposed as factors that regulate ERAD. As explained above,
several DUBs have been reported to interact with p97/VCP and function as positive
regulators of retrotranslocation. Additionally, some DUBs are linked with the regu-
lation of E3 enzyme stability. For example, USP19, an ER-anchored DUB, rescues
HRD1 from proteasomal degradation and thereby regulates HRD1 stability [120].
Similarly, USP19 enhances the stability and activity of another E3 MARCH6 [121].
SVIP (small VCP interacting protein), a VCP-interaction motif (VIM)
containing protein, is the first identified endogen ERAD inhibitor. SVIP interacts
with p97/VCP and Derlin1 and inhibits the ubiquitination and degradation of gp78-
dependent ERAD substrates [111]. Another endogen ERAD inhibitor is SAKS1.
SAKS1 binds to the polyubiquitin chain of the substrate and p97/VCP and attenu-
ates the ERAD process [122].
ERAD activity can also be controlled by hormonal regulation. Glucocorticoids
have been suggested to ameliorate ER stress by promoting correct folding of
secreted proteins and enhancing removal of misfolded proteins from the ER proba-
bly through induction of UPR. Recently, androgen-mediated regulation of ERAD
has been reported. Androgen treatment upregulated the expression of Os9, p97/
VCP, Ufd1, Npl4, Hrd1 and gp78, but downregulated ERAD inhibitor SVIP, which
in turn enhanced the proteolytic activity of ERAD in androgen-sensitive prostate
cancer cells [123]. Furthermore, the regulation of ERAD by androgen is mediated
via AR and is partially or fully independent on the androgen-mediated induction of
IRE1α branch [123].
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